Influence of nutrient correction on adiponectin circulating level and cardiovascular risk factors in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease

Main Article Content

I.P. Dunayeva


Aim — to evaluate the influence of dietary recommendations on adiponectin circulating level and haemodynamic characteristics in patients with type 2 diabetes mellitus (DM) and non-alcoholic fatty liver disease. Materials and methods. 34 patients with type 2 DM and non-alcoholic fatty liver disease were examined (15 women and 19 men) with duration of disease of 10.37 ± 1.00 years. The average age of patients was 61.09 ± 1.76 years. Results. The article presents the results of the effect of standard treatment with inclusion of nutrient therapy in type 2 DM patients with non-alcoholic fatty liver disease on adiponectin circulating level and hemodynamics, echocardiographic characteristics and structural-functional condition of the vessels. A significant increase of adiponectin level was found. The greatest effect is defined in terms of normalization of the blood pressure. Then follow the impact on the left ventricular mass and then — on the normalization of the left ventricular cavity. Very low effect was found on the norma­lization of left ventricular systolic function (ejection fraction).Conclusions. The analysis of the dynamics of diastolic function indicators showed the increase of the early left ventricular filling velocity, the decrease in the late left ventricular filling velocity, as well as the growth of their relations. The analysis of the structural-functional condition of the vessels showed the decrease of pulse wave velocity in the carotid artery and abdominal aorta, the growth of the endothelium-dependent vasodilation degree in the absence of significant changes in the thickness of the intima-media.

Article Details

How to Cite
Dunayeva, I. “Influence of Nutrient Correction on Adiponectin Circulating Level and Cardiovascular Risk Factors in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 13, no. 1, Feb. 2017, pp. 18-26, doi:10.22141/2224-0721.13.1.2017.96751.
Original Researches


International Diabetes Federation (IDF). Diabetes Atlas. 7th ed. Vancouver, Canada, 2015.

Mankovsky BM. Prevalence of the un diagnosed type 2 diabetes mellitus and prediabetes in Ukraine: results of epidemiology research Diapazon. Diabet. Ozhyrinnia. Metabolichnyj syndrom. 2014;5:70-75 (Ukrainian).

Levit Sh., Filippov YI, Gorelyshev AS. Type 2 diabetes mellitus: time to change conception. Diabetes mellitus. 2013;1:91-102 (Russian).

DeFronzo RA. Insulin resistance, lipotoxity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010;53:1270-1287.

Karachentsev YI, Gorshunska MY, Kravchun NO et al. One nucleotide adiponectin gene polymorphism (+276Т) and expression of insulin resistance state constituents in patients with type 2 diabetes mellitus. Problemy endokrynnoi patologii. 2013;2:7-17 (Ukrainian).

Rydén L, Grant PJ, Anker SD et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Russ J Cardiol. 2014; 107(3):7-61.

Schwimmer JB, Behling C, Newbury R et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005;42(3):641-649.

Setji TL, Holland ND, Sanders LL et al. Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(5):1741-1747.

Pan’kiv VI. Insulin resistance as key pathophysiological mechanism of metabolic syndrome development. Praktychna angiologia. 2012;5/6:24-28 (Ukrainian).

Mykhalchuk LM, Efimov AS. Non-alcoholic fatty liver disease. International Journal of Endocrinology. 2010;2(26):71-82 (Ukrainian).

Bodnar PM, Mykhalchyshyn HP, Kobyliak NM. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Endokrynologia. 2012;17(1):94-101 (Ukrainian).

Sobel BE. Coronary revascularization in patients with type 2 diabetes and results of the BARI 2D trial. Coron Artery Dis. 2010;21(3):189-198.

Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26(3):439-451.

Ahima RS, Miller RA, Chu Q et al. Adiponectin suppresses gluconeogenic gene expression in mouse hepatocytes independent of LKB1-AMPK signaling. J Clin Invest. 2011;121(6):2518-2528.

Gorshunska MY. Total and high molecular adiponectin weight in patients with type 2 diabetes mellitus taking into account of sex, glycemic control and degree of insulinersistance. Problemy endokrynnoi patologii. 2012;2:91-107 (Ukrainian).

Popovic V, Mattsson AF, Gaillard RC et al. Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database). J Clin Endocrinol Metab. 2010;95(9):4449-4454.

Dyck DJ, Heigenhauser GJ, Bruce CR. The role of adipokines as regulators of skeletal muscle fatty acid metabolism and insulin sensitivity. Acta Physiol (Oxf). 2006;186(1):5-16.

Shvarz VY. Adiponectin: pathophysiological aspects. Patologicheskaya fiziologia i eksperimentalnaya terapiya. 2009;3:34-38 (Russian).

Kourliouros AK, Gukop P, Hosseini MT et al. Protective effect of epicardial adiponectin release on atrial fibrillation following cardiac surgery. Oxford Journals Medicine & Health Interactive CardioVasc Thoracic Surgery. 2009;9(2):87.

Hotta K, Lange H, Tantillo DJ. еt al. Catalysis of decarboxylation by a preorganized heterogeneous microenvironment: crystal structures of abzyme. J Mol Biol. 2000;302(5):1213-1225.

Yamauchi J, Chan JR, Shooter EM. Neurotrophin 3 activation of TrkC induces Schwann cell migration through the c-Jun N-terminal kinase pathway. Proc Natl Acad Sci USA. 2003;100(24):14421-1446.

Ouchi N, Kihara S, Funahashi T. et al. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol. 2003;14(6):561-566.

Bråkenhielm E, Veitonmäki N, Cao R. et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA. 2004;101(8):2476-2481.

Barnea MN, Chapnik N, Genzer Y et al. The circadian clock machinery controls adiponectin expression. Mol Cell Endocrinol. 2015;399:284-287.

Song X, Liu X, Cai L, Sheng WY, Gong CX et al. Construction of cTnC-linker-TnI (P) Genes, Expression of Fusion Protein and Preparation of Lyophilized Protein. 2015;32(6):1267-1272.

Ma XQ, Wang M, Xu XX et al. Identification of Volatile Chemical Constituents from Hui Formula "Ha Hei Lili" by GC-MS. 2015;38(10):2176-2179.

Ghoshal K, Bhattacharyya M. Adiponectin: Probe of the molecular paradigm associating diabetes and obesity. World J Diabetes. 2015;6(1):151-166.

Orio FJ, Palomba S, Cascella T et al. Adiponectin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003; 88(6):2619-2623.

Glintborg D, Andersen M, Hagen C et al. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. 2006;155(2):337-345.

Risch L, Hoefle G, Saely C et al. Evaluation of two fully automated novel enzyme-linked immunosorbent assays for the determination of human adiponectin in serum. Clin Chim Acta. 2006;373(1-2):121-126.

Kaplan RC, Ho GY, Xue X et al. Within-individual stability of obesity-related biomarkers among women. Cancer Epidemiol. Biomarkers Prev. 2007;16(6):1291-1293.

Carmina E, Orio F, Palomba S et al. Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol. 2005;152(3):389-394.

Hill MJ, Kumar S, McTernan PG. Adipokines and the clinical laboratory: what to measure, when and how? J Clin Pathol. 2009;62(3):206-211.

Berg AH, Berg TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab. 2002;13(2):84-89.

Vega GL, Grundy SM. Metabolic risk susceptibility in men is partially related to adiponectin/leptin ratio. J Obes. 2013;10:49-67.

Gorshkov IP, Zoloedov VI. Role of adipocynesin type 2 diabetes mellitus and metabolic syndrome pathogenesis (review). Vestnik novykh meditsinskikh tehnologiy. 2010;17(1):132-134 (Russian).

Solomon SS, Odunusi O, Carrigan D et al. TNF-alpha inhibits insulin action in liver and adipose tissue: A model of metabolic syndrome. Horm Metab Res. 2010; 42(2):115-121.

Lorenzo M, Fernández-Veledo S, Vila-Bedmar R et al. Insulin resistance induced by tumor necrosis factor-alpha in myocytes and brown. J Anim Sci. 2008;86(14):94-104.

Bremer AA, Jialal L. Adipose tissue dysfunction in nascent metabolic syndrome. J Obes. 2013;9:31-39.

Finucane OM, Reynolds CM, McGillicuddy FC. еt al. Insights into the role of macrophage migration inhibitory factor in obesity and insulin resistance. Proc Nutr Soc. 2012;71(4):622-633.

Liu Y, Li D, Zhang Y et al. Anthocyanin increases adiponectin secretion and protects against diabetes-related endothelial. Am J Physiol Endocrinol Metab. 2014;306(8):975-988.

Yu LX, Zhou NN, Liu LY еt al. Adiponectin receptor 1 (ADIPOR1) rs1342387 polymorphism and risk of cancer: a meta-analysis. Asian Pac J Cancer Prev. 2014;15(18):15-20.

Correnti JM, Juskeviciute E, Swarup A et al. Pharmacological ceramide reduction alleviates alcohol-induced steatosis and hepatomegaly in adiponectin knockout mice. Am J Physiol Gastrointest Liver Physiol. 2014;306;959-973.

Poltorak VV, Gorshunska MY, Krasova NS. Adiponectin and type 2 diabetes mellitus (pathophysiological aspects as background of antidiabetic pharmacological therapy optimization).Inrernational Journal of Endocrinology. 2014;5:95-104 (Ukrainian).

Uribarri JS, Woodruff S, Goodman S et al. Advanced Glycation End Products in Foods and a Practical Guide to Their Reduction in the Diet. Am Diet Assoc. 2010;110(6):911-916.

Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820.

Bohlender JM, Franke S, Stein G, Wolf G. Advanced glycation end products and the. Am J Physiol Renal Physiol. 2005;289:645-659.

O’Brien J, Morrissey PA. Nutritional and toxicological aspects of the Maillard browning reaction in foods. Crit Rev Food Sci Nutr. 1989;28:211-248.

Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res. 2001;56:1-21.

Eble AS, Thorpe SR, Baynes JW. Nonenzymatic glycosylation and glucose-dependent cross-linking of proteins. Biol Chem. 1983;258:9406-9412.

Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Rev. 2001;17:436-443.

Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res. 1999;84:489-497.

Abordo EA, Minhas, Thornalley PJ. Accumulation of alpha-oxoaldehydes during oxidative stress: A role in cytotoxicity. Biochem Pharmacol. 1999;58:641-648.

Fu MX, Requena JR, Jenkins AJ et al. The advanced glycation endproduct N-[carboxymethyl]-lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem. 1996;271:9982-9986.

Goldberg T, Cai W, Peppa M et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc. 2004;104;1287-1291.

Lin RY, Choudhury RP, Cai W et al. Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. 2003;168:213-220.

Zheng F, He C, Cai W. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev. 2002;18:224-237.

Lin RY, Reis RY, Reis D, Dore AT еt al. Lowering of dietary advanced glycation endproducts (AGEs) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice. Atherosclerosis. 2002;163:303-311.

Peppa M, He C, Hattori M еt al. Fetal or neonatal low-glycotoxin environment prevents autoimmune diabetes in NOD mice. Diabetes. 2003;52:1441-1445.

Hofmann SM, Dong HJ, Li Z et al. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes. 2002;51:2082-2089.

Sandu O, Song K, Cai W et al. Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes. 2005;54:2314-2319.

Peppa M, Brem H, Ehrlich P. Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice. Diabetes. 2003;52:2805-2813.

Uribarri J, Cai N, Peppa M. Circulating glycotoxins and dietary advanced glycation end-products: Two links to inflammatory response oxidative stress, and aging. J Gerontol A Biol Sci Med Sci. 2007;62:427-433.

Vlassara H, Uribarri J. Glycoxidation and diabetic complications: Modern lessons and a warning? Rev Endocrin Metab Disord. 2004;5:181-188.

Uribarri J, Goodman S et al. Advanced Glycation End Products in Foods and a Practical Guide to Their Reduction in the Diet. Am Diet Assoc. 2010;110(6):1-27.

Kovalyova O, Nyzhegorodtseva O. Left ventricular remodeling and tumor necrosis factor-alpha on hypertension. Eur J Echocardiography. 2002;3(1):15.

Dunaeva IP, Dorosh OG, Karachentsev YI. Nutrient correction in patients with type 2 diabetes mellitus and non-alcoholic fatty liver. East European Scientific Journal. 2016;6:41-53 (Russian).